IP Library › Patent Application 13215883
Patent Application
App. No. 13/215,883

Tumor Antigens BFA5 for Prevention and/or Treatment of Cancer

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/215,883
Abstract

The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Claims (21)

1 - 63 . (canceled)

64 . An expression vector comprising the nucleic acid sequence as illustrated in

SEQ ID NO.: 5 or a fragment thereof.

65 . The expression vector of claim 64 wherein the vector is a plasmid or a viral vector.

66 . The expression vector of claim 65 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.

67 . The expression vector of claim 66 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

68 . The expression vector of claim 66 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

69 . The expression vector of claim 1 further comprising at least one additional tumor-associated antigen.

70 . An isolated peptide derived from BFA5 as shown in Table X or XI.

71 . A method for immunizing a host against the tumor antigen BFA5 comprising administering to the patient a peptide of claim 74 , either alone or in combination with another agent, where the individual components of the combination are administered simultaneously or separately from one another.

72 . An expression vector comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO.: 6 or a fragment thereof.

73 . A composition comprising an expression vector of claim 1 and a pharmaceutically acceptable carrier.

74 . A composition comprising an expression vector of claim 76 and a pharmaceutically acceptable carrier.

75 . An antibody having the ability to bind the amino acid sequence of SEQ ID NO.: 6 or a fragment thereof.

76 . The antibody of claim 79 wherein the fragment is selected from the group consisting of SEQ ID NO.:7, SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, SEQ ID NO.:70, SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, and SEQ ID NO.:85.

77 . A composition comprising an antibody of claim 79 and a pharmaceutically acceptable carrier.

78 . A composition comprising an antibody of claim 80 and a pharmaceutically acceptable carrier.

79 . An isolated peptide selected from the group consisting of SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, and SEQ ID NO.:12.

80 . A composition comprising an isolated peptide of claim 79 and a pharmaceutically acceptable carrier.

81 . A method for inducing an immune response against the tumor antigen BFA5 (SEQ ID NO.: 6) in a host comprising administering to the host the isolated peptide of claim 79 .

82 . A method for inducing an immune response against the tumor antigen BFA5 (SEQ ID NO.: 6) in a host comprising administering to the host the composition of claim 79 .